applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551–0001, not later than January 2, 2024.

- A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414. Comments can also be sent electronically to Comments.applications@chi.frb.org:
- 1. The Joshua Guttau Generational Irrevocable Trust and the Heidi A. Guttau Generational Irrevocable Trust, Scott Braden and Lyse Wells as cotrustees, all of Treynor, Iowa; to join the Guttau Family Control Group, a group acting in concert, to each acquire 23.47 percent of the voting shares of Treynor Bancshares, Inc., Treynor, Iowa, and thereby indirectly acquire voting shares of TS Bank, Treynor, Iowa, Bank of Tioga, Tioga, North Dakota, and First National Bank and Trust Company, Clinton, Illinois.

This notice is related to the document, Formations of, Acquisitions by, and Mergers of Bank Holding Companies, *Treynor Bancshares, Inc. et als.*; published elsewhere in today's issue of the **Federal Register**.

Board of Governors of the Federal Reserve System.

### Michele Taylor Fennell,

Deputy Associate Secretary of the Board. [FR Doc. 2023–27776 Filed 12–18–23; 8:45 am]

BILLING CODE P

## GENERAL SERVICES ADMINISTRATION

[Notice-MY-2023-04; Docket No. 2023-0002; Sequence No. 46]

Senior Policy Operating Group's Procurement and Supply Chains Committee Outreach Session

**AGENCY:** Office of Government-wide Policy, General Services Administration (GSA).

**ACTION:** Notice of public meeting.

SUMMARY: GSA is providing notice of a public meeting on behalf of the Chief Acquisition Officers Council (CAOC) and the Senior Policy Operating Group's (SPOG) Procurement and Supply Chains Committee to build understanding and awareness about the anti-human trafficking requirements of the Federal Acquisition Regulation (FAR), share information about U.S. government tools and reporting to assist with compliance, and to discuss actions the Federal Government can take to achieve more effective implementation.

DATES: The SPOG Procurement and Supply Chains Committee will hold a web-based open public meeting on Thursday, January 18th, from 11 a.m. to 1 p.m. Eastern Standard Time (EST). ADDRESSES: The meeting will be

**ADDRESSES:** The meeting will be accessible via webcast. Registrants will receive the webcast information before the meeting.

## FOR FURTHER INFORMATION CONTACT:

Shenaye Holmes, Senior Advisor, General Services Administration, Office of Government-wide Policy, 202–213– 2922 or email: shenaye.holmes@gsa.gov; or Harry D'Agostino, harry.dagostino@ gsa.gov.

### SUPPLEMENTARY INFORMATION:

## **Background**

The National Action Plan to Combat Human Trafficking (available at: https:// www.whitehouse.gov/wp-content/ uploads/2021/12/National-Action-Planto-Combat-Human-Trafficking.pdf) Priority Action 1.3.1 calls on the Chief Acquisition Officers to support a public outreach session hosted by the SPOG Procurement and Supply Chains Committee (the Committee) for contracting companies, nongovernmental organizations, international partners, associates of State, local, Tribal, and Territorial officials, and any interested parties to build understanding and awareness about the anti-trafficking requirements of the FAR. Policy officials from the Committee will review recent efforts to prevent and address human trafficking in Federal supply chains and invite

members of the public to provide input on ways to strengthen implementation of anti-trafficking requirements in Federal acquisition.

The first public meeting was held in January 2023 (88 FR 863). This will be the second public meeting and topics will include, but not be limited to the following: (1) experience with OMB Memorandum M-20-01, Anti-Trafficking Risk Management Best Practices & Mitigation Considerations, (2) trainings and resources for government and contractors, (3) using internal government findings, such as the Department of Labor's List of Products Produced by Forced or Indentured Child Labor, to assist in analyzing supply chains, and (4) developments in combating trafficking in global supply chains that would be helpful to apply to Federal procurement.

Additionally, we are particularly interested in hearing from stakeholders regarding the following anti-trafficking related efforts:

- 1. Promising practices in creating a supply chain due diligence program, including implementing a compliance plan to prevent and address the prohibited activities listed in FAR 52.222–50;
- 2. Successful awareness and training programs that inform employees about the FAR's prohibitions against trafficking-related activities;
- 3. Increasing the ability of workers to report violations and suspected violations; and
- 4. Examples of effective remediation.

## **Meeting Registration**

The meeting is open to the public. The meeting will be accessible by webcast. Registration is required for web viewing. To register, go to: https://gsa.zoomgov.com/webinar/register/WN\_2UYgv6xbQDGNh2ixMEIQaA#/registration.

Attendees must register by 5:00 p.m., on January 11, 2024. All registrants will be asked to provide their name, affiliation, and email address. After registration, individuals will receive webcast access information via email. Additionally, using the registration page, registrants will be able to submit questions for the Committee or whether they wish to present recommendations or lessons learned during the meeting.

### **Special Accommodations**

For information on services for individuals with disabilities, or to request accommodation of a disability, please contact the Designated Federal Officer at least 10 business days prior to the meeting to give GSA as much time

as possible to process the request. Closed captioning and live ASL interpreter services will be available.

### Shenayé V. Holmes,

Senior Advisor, Federal Privacy Council, Made in America Council, Chief Acquisition Officers Council.

[FR Doc. 2023–27781 Filed 12–18–23; 8:45 am] BILLING CODE 6820–69–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2023-D-1716]

Registration and Listing of Cosmetic Product Facilities and Products; Guidance for Industry; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled "Registration and Listing of Cosmetic Product Facilities and Products." The guidance will assist persons submitting cosmetic product facility registrations and product listing submissions to FDA under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This guidance also includes a new draft section, Appendix B, for comment purposes only, that describes frequently asked questions and answers about cosmetic product facility registrations and product listing submissions. Aside from that section, this guidance finalizes the draft guidance that was published on August 8, 2023.

DATES: The announcement of the guidance is published in the Federal Register on December 19, 2023. However, the portion of this guidance that describes frequently asked questions and answers, is being distributed for comment purposes only. To ensure that the Agency considers your comment on this draft section before it begins work on the final version of this section of the guidance, submit either electronic or written comments on this section by January 18, 2024.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidances at any time as follows:

### Electronic Submissions

Submit electronic comments in the following way:

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.

• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

## Written/Paper Submissions

Submit written/paper submissions as follows:

- Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA—2023—D—1716 for "Registration and Listing of Cosmetic Product Facilities and Products." Received comments will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240—402—7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in

its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the guidance to Office of Cosmetics and Colors, Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 5001 Campus Dr., College Park, MD 20740. Send two self-addressed adhesive labels to assist that office in processing your request. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance.

### FOR FURTHER INFORMATION CONTACT:

Jennifer Ross, Office of the Chief Scientist, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4332, Silver Spring, MD 20993–0002, 301–796–4880 (this is not a toll-free number), email: QuestionsAboutMoCRA@fda.hhs.gov.

## SUPPLEMENTARY INFORMATION:

## I. Background

We are announcing the availability of a guidance for industry entitled "Registration and Listing of Cosmetic Product Facilities and Products." We are issuing this guidance consistent with our good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on this topic. It does not